Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT ID: NCT05099471
Last Updated: 2025-11-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-03-21
Study Completion Date
2033-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities. Thus, innovative approaches are needed which combine excellent activity and tolerability in WM. Chemotherapy-free approaches are highly attractive for this patient group. Based on its high activity and favorable toxicity profile in indolent B-NHL such as CLL, Venetoclax was approved for the treatment of this diseases by the FDA and the European Medicines Agency (EMA). First data in relapsed/refractory WM have documented high activity and low toxicity of Venetoclax also in WM, including patients with prior Ibrutinib treatment or patients carrying CXCR4 mutations. Ibrutinib itself has high activity and a relatively low toxicity profile in WM, but has also major disadvantages: the main disadvantage is the need to apply this drug continuously. Furthermore, Ibrutinib efficacy depends largely on the genotype with a substantial drop in major responses and PFS in the presence of CXCR4 mutations and non-mutated MYD88. In particular the need of continuous treatment for Ibrutinib has prevented that Ibrutinib has become the standard of care outcompeting conventional Rituximab/chemotherapy. This is reflected in current guidelines such as the NCCN and the ESMO guidelines, which still see immunochemotherapy as a backbone of treatment, largely because of the advantage of a timely fixed application. Data in CLL in the relapsed as well as in the first line setting have convincingly shown that in contrast to Ibrutinib Venetoclax is highly efficient also when used in a timely defined application scheme over 12 months in combination with the anti-CD20 antibody Rituximab. Data documented deep responses including molecular responses and a highly significant advantage over immunochemotherapy in large international Phase III trials, changing the standard of care in this disease.
Based on this the hypothesis is that timely fixed application of the combination of Venetoclax and Rituximab induces significantly superior treatment outcomes compared to chemotherapy and Rituximab (DRC) in patients with treatment naïve WM, regardless of the genotype. A first indication for this assumption in the proposed trial will allow the performance of confirmatory phase 3 trials that might change the standard of care in WM.
Based on this the hypothesis is that timely fixed application of the combination of Venetoclax and Rituximab induces significantly superior treatment outcomes compared to chemotherapy and Rituximab (DRC) in patients with treatment naïve WM, regardless of the genotype. A first indication for this assumption in the proposed trial will allow the performance of confirmatory phase 3 trials that might change the standard of care in WM.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT04840602
Lymphoplasmacytic Lymphoma
Waldenstrom Macroglobulinemia
SUSPENDED
PHASE2
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
NCT03630042
Waldenstrom Macroglobulinemia
COMPLETED
PHASE2
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
NCT03567876
Lymphoma, Mantle-Cell
COMPLETED
PHASE2
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00005609
Lymphoma
COMPLETED
PHASE2
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
NCT03255096
Diffuse Large B-cell Lymphoma
High-Grade B-cell Lymphoma
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities. Thus, innovative approaches are needed which combine excellent activity and tolerability in WM. Chemotherapy-free approaches are highly attractive for this patient group. Based on its high activity and favorable toxicity profile in indolent B-NHL such as CLL, Venetoclax was approved for the treatment of this diseases by the FDA and the European Medicines Agency (EMA). First data in relapsed/refractory WM have documented high activity and low toxicity of Venetoclax also in WM, including patients with prior Ibrutinib treatment or patients carrying CXCR4 mutations. Ibrutinib itself has high activity and a relatively low toxicity profile in WM, but has also major disadvantages: the main disadvantage is the need to apply this drug continuously. Furthermore, Ibrutinib efficacy depends largely on the genotype with a substantial drop in major responses and PFS in the presence of CXCR4 mutations and non-mutated MYD88. In particular the need of continuous treatment for Ibrutinib has prevented that Ibrutinib has become the standard of care outcompeting conventional Rituximab/chemotherapy. This is reflected in current guidelines such as the NCCN and the ESMO guidelines, which still see immunochemotherapy as a backbone of treatment, largely because of the advantage of a timely fixed application. Data in CLL in the relapsed as well as in the first line setting have convincingly shown that in contrast to Ibrutinib Venetoclax is highly efficient also when used in a timely defined application scheme over 12 months in combination with the anti-CD20 antibody Rituximab. Data documented deep responses including molecular responses and a highly significant advantage over immunochemotherapy in large international Phase III trials, changing the standard of care in this disease.
Based on this the hypothesis is that timely fixed application of the combination of Venetoclax and Rituximab induces significantly superior treatment outcomes compared to chemotherapy and Rituximab (DRC) in patients with treatment naïve WM, regardless of the genotype. A first indication for this assumption in the proposed trial will allow the performance of confirmatory phase 3 trials that might change the standard of care in WM.
This study is an International phase II explorative, multicenter, open label, and randomized trial.
The study will consist of an open labeled, stratified 1:1 randomization between Arm A and Arm B for de novo WM patients in need of treatment (phase II). Stratification factors are MYD88 and CXCR4 status (positive vs. negative). A stratified central block randomization will be used. The central randomization service will be used to avoid predictability of the treatment arm.
The primary goal of this study is to explore the efficacy of Venetoclax plus Rituximab versus Dexamethasone/Cyclophosphamide/Rituximab in the treatment of de novo WM patients (Arm A vs. Arm B).
80 patients are planned to be recruited for this study at approcimately 30 sites in Germany, Greece and France.
Based on this the hypothesis is that timely fixed application of the combination of Venetoclax and Rituximab induces significantly superior treatment outcomes compared to chemotherapy and Rituximab (DRC) in patients with treatment naïve WM, regardless of the genotype. A first indication for this assumption in the proposed trial will allow the performance of confirmatory phase 3 trials that might change the standard of care in WM.
This study is an International phase II explorative, multicenter, open label, and randomized trial.
The study will consist of an open labeled, stratified 1:1 randomization between Arm A and Arm B for de novo WM patients in need of treatment (phase II). Stratification factors are MYD88 and CXCR4 status (positive vs. negative). A stratified central block randomization will be used. The central randomization service will be used to avoid predictability of the treatment arm.
The primary goal of this study is to explore the efficacy of Venetoclax plus Rituximab versus Dexamethasone/Cyclophosphamide/Rituximab in the treatment of de novo WM patients (Arm A vs. Arm B).
80 patients are planned to be recruited for this study at approcimately 30 sites in Germany, Greece and France.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Waldenstrom Macroglobulinemia
Treatment Naive
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Venetoclax / Rituximab
Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of xy mg/d QD PO.
Day 1-7: Venetoclax xy mg/d QD PO Day 8-14: Venetoclax xy mg/d QD PO Day 15-28: Venetoclax xy mg/d QD PO
Cycle 2-12:
Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax xy mg/d QD PO
Group Type
EXPERIMENTAL
Venetoclax; Rituximab
Intervention Type
DRUG
Combination of venetoclax and rituximab
Dexamethasone / Rituximab / Cyclophosphamide
Cycle 1-6:
Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO
Group Type
ACTIVE_COMPARATOR
DRC
Intervention Type
DRUG
Combination of Dexamethasone / Rituximab / Cyclophosphamide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venetoclax; Rituximab
Combination of venetoclax and rituximab
Intervention Type
DRUG
DRC
Combination of Dexamethasone / Rituximab / Cyclophosphamide
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Venetoclax / Rituximab
Dexamethasone / Rituximab / Cyclophosphamide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proven clinicopathological diagnosis of WM as defined by consensus panel one of the Second International Workshop on WM (IWWM). Histopathology has to be perfomed before randomization but within the last 4 months before start of treatment. In addition, pathological specimens have to be sent to the national pathological reference center prior to randomization for the determination of the mutational status of MYD88 and CXCR4 prior to randomization if the mutational status hasn't been determined before. Pathological reference center must confirm the diagnosis of WM.
* De novo WM independent of the genotype.
* Patients must have at least one of the following criteria to start study treatment as partly defined by consensus panel criteria from the Seventh IWWM and ESMO Guideline:
* Recurrent fever, night sweats, weight loss, fatigue (at least one of them).
* Hyperviscosity.
* Lymphadenopathy which is either symptomatic or bulky (≥ 5 cm in maximum diameter).
* Symptomatic hepatomegaly and / or splenomegaly.
* Symptomatic organomegaly and / or organ or tissue infiltration.
* Peripheral neuropathy due to WM.
* Symptomatic cryoglobulinemia.
* Symptomatic Cold agglutinin anemia.
* Autoimmune hemolytic anemia and/or thrombocytopenia.
* Nephropathy related to WM.
* Amyloidosis related to WM.
* Hemoglobin ≤ 10 g/dL (patients should not have received red blood cells transfusions for at least 7 days prior to obtaining the screening hemoglobin).
* Platelet count \< 100 x 109/L (caused by bone marrow \[BM\] infiltration of the lymphoma).
* Serum monoclonal protein \> 5 g/dL, even with no overt clinical symptoms.
* IgM serum concentration ≥ 6 g/dL.
* and other WM associated relevant symptoms
* Subject must be ≥ 18 years of age.
* Life expectancy \> 3 months.
* World Health Organization (WHO) / ECOG performance status ≤ 2.
* Left ventricular ejection fraction ≥ 40% as assessed by transthoracic echocardiogram (TTE).
* Baseline platelet count ≥ 50x109/L, absolute neutrophil count ≥ 0.75x109/L (if not due to BM infiltration by the lymphoma).
. Adequate hepatic function per local laboratory reference range as follows:
* Aspartate transaminase (AST) and alanine transaminase (ALT) \< 3.0 x ULN.
* Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
* Subject must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
* Women of childbearing potential (WCBP), i.e. fertile, following menarche and until becoming postmenopausal must have negative results for pregnancy test and must agree to use a highly effective method of birth control for the duration of the therapy up to 12 months after end of therapy
* Men must agree not to father a child for the duration of therapy and 12 months after and must agree to advice their female partner to use a highly effective method of birth control. Males must refrain from sperm donation for the duration of treatment and at least 12 months after the last dose of study medication.
* Each patient must voluntarily date and sign an informed consent form in the native language of the patient indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
* Affiliation to a social security scheme (relevant for France only).
* De novo WM independent of the genotype.
* Patients must have at least one of the following criteria to start study treatment as partly defined by consensus panel criteria from the Seventh IWWM and ESMO Guideline:
* Recurrent fever, night sweats, weight loss, fatigue (at least one of them).
* Hyperviscosity.
* Lymphadenopathy which is either symptomatic or bulky (≥ 5 cm in maximum diameter).
* Symptomatic hepatomegaly and / or splenomegaly.
* Symptomatic organomegaly and / or organ or tissue infiltration.
* Peripheral neuropathy due to WM.
* Symptomatic cryoglobulinemia.
* Symptomatic Cold agglutinin anemia.
* Autoimmune hemolytic anemia and/or thrombocytopenia.
* Nephropathy related to WM.
* Amyloidosis related to WM.
* Hemoglobin ≤ 10 g/dL (patients should not have received red blood cells transfusions for at least 7 days prior to obtaining the screening hemoglobin).
* Platelet count \< 100 x 109/L (caused by bone marrow \[BM\] infiltration of the lymphoma).
* Serum monoclonal protein \> 5 g/dL, even with no overt clinical symptoms.
* IgM serum concentration ≥ 6 g/dL.
* and other WM associated relevant symptoms
* Subject must be ≥ 18 years of age.
* Life expectancy \> 3 months.
* World Health Organization (WHO) / ECOG performance status ≤ 2.
* Left ventricular ejection fraction ≥ 40% as assessed by transthoracic echocardiogram (TTE).
* Baseline platelet count ≥ 50x109/L, absolute neutrophil count ≥ 0.75x109/L (if not due to BM infiltration by the lymphoma).
. Adequate hepatic function per local laboratory reference range as follows:
* Aspartate transaminase (AST) and alanine transaminase (ALT) \< 3.0 x ULN.
* Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
* Subject must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
* Women of childbearing potential (WCBP), i.e. fertile, following menarche and until becoming postmenopausal must have negative results for pregnancy test and must agree to use a highly effective method of birth control for the duration of the therapy up to 12 months after end of therapy
* Men must agree not to father a child for the duration of therapy and 12 months after and must agree to advice their female partner to use a highly effective method of birth control. Males must refrain from sperm donation for the duration of treatment and at least 12 months after the last dose of study medication.
* Each patient must voluntarily date and sign an informed consent form in the native language of the patient indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
* Affiliation to a social security scheme (relevant for France only).
Exclusion Criteria
* Serious medical or psychiatric illness (especially undergoing treatment) likely to interfere with participation in this clinical study.
* Subject is known to be positive for HIV.
* Active severe infection
* Congenital or acquired severe immunodeficiency not attributed to lymphoma (clinical appearance: recurrent infections, necessity of immunoglobulin substitution therapy, patients after transplantation)
* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
* Uncontrolled systemic infection (viral, bacterial or fungal).
* Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate
* inadequate pulmonary function as demonstrated by DLCO ≤ 65% or FEV1 ≤ 65%.
* Creatinine clearance ≥ 30 mL/min to \< 45 ml/min
* Uncontrolled diabetes mellitus (as indicated by metabolic derangements and / or severe diabetes mellitus related uncontrolled organ complications).
* Uncontrolled hypertension.
* Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 50% or chronic stable angina.
* Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months prior to start therapy.
* Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia.
* Subject has a cardiovascular disability status of New York Heart Association Class \> 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
* History of stroke or intracranial haemorrhage within 6 months prior start of treatment
* Known pericardial disease.
* Known interstitial lung disease.
* Infiltrative pulmonary disease, known pulmonary hypertension.
* Prior history of malignancies unless the subject has been free of the disease for ≥ 3 years. Exceptions include the following:
* Basal cell carcinoma of the skin,
* Squamous cell carcinoma of the skin,
* Carcinoma in situ of the cervix,
* Carcinoma in situ of the breast,
* Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b).
* Known cirrhosis (meeting child-pugh stage C).
* Chemotherapy with approved or investigational anticancer therapeutic within 21 days prior to start of therapy
* Glucocorticoid therapy within 14 days prior to therapy that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent dose of other corticosteroids given for anti-neoplastic intent.
* Treatment with any of the following within 7 days prior to the first dose of study drug:
* moderate or strong cytochrome P450 3A (CYP3A) inhibitors (such as fluconazole, ketoconazole, and clarithromycin).
* moderate or strong CYP3A inducers (such as rifampin, carbamazepine, phenytoin, St. John's wort).
* Contraindication to the active substances or any of the other excipients of the Investigational Medicinal Products as well as to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs.
* Vaccination with live attenuated vaccines within 4 weeks prior to start of therapy.
* History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or sponsor, if consulted, would pose a risk to subject safely or interfere with the study evaluation, procedures or completion.
* Women who are pregnant as well as women who are breast-feeding and do not consent to discontinue breast-feeding.
* Participation in another clinical trial within four weeks before start of therapy in this study.
* No consent for registration, storage and processing of the individual disease-characteristics.
* Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
* grapefruit or grapefruit products.
* Seville oranges (including marmalade containing Seville oranges).
* star fruit.
* Person of legal age who is incapable of comprehending the nature, significance and implications of the clinical trial and of determining his/her will in the light of these facts
* Subject is known to be positive for HIV.
* Active severe infection
* Congenital or acquired severe immunodeficiency not attributed to lymphoma (clinical appearance: recurrent infections, necessity of immunoglobulin substitution therapy, patients after transplantation)
* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
* Uncontrolled systemic infection (viral, bacterial or fungal).
* Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate
* inadequate pulmonary function as demonstrated by DLCO ≤ 65% or FEV1 ≤ 65%.
* Creatinine clearance ≥ 30 mL/min to \< 45 ml/min
* Uncontrolled diabetes mellitus (as indicated by metabolic derangements and / or severe diabetes mellitus related uncontrolled organ complications).
* Uncontrolled hypertension.
* Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 50% or chronic stable angina.
* Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months prior to start therapy.
* Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia.
* Subject has a cardiovascular disability status of New York Heart Association Class \> 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
* History of stroke or intracranial haemorrhage within 6 months prior start of treatment
* Known pericardial disease.
* Known interstitial lung disease.
* Infiltrative pulmonary disease, known pulmonary hypertension.
* Prior history of malignancies unless the subject has been free of the disease for ≥ 3 years. Exceptions include the following:
* Basal cell carcinoma of the skin,
* Squamous cell carcinoma of the skin,
* Carcinoma in situ of the cervix,
* Carcinoma in situ of the breast,
* Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b).
* Known cirrhosis (meeting child-pugh stage C).
* Chemotherapy with approved or investigational anticancer therapeutic within 21 days prior to start of therapy
* Glucocorticoid therapy within 14 days prior to therapy that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent dose of other corticosteroids given for anti-neoplastic intent.
* Treatment with any of the following within 7 days prior to the first dose of study drug:
* moderate or strong cytochrome P450 3A (CYP3A) inhibitors (such as fluconazole, ketoconazole, and clarithromycin).
* moderate or strong CYP3A inducers (such as rifampin, carbamazepine, phenytoin, St. John's wort).
* Contraindication to the active substances or any of the other excipients of the Investigational Medicinal Products as well as to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs.
* Vaccination with live attenuated vaccines within 4 weeks prior to start of therapy.
* History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or sponsor, if consulted, would pose a risk to subject safely or interfere with the study evaluation, procedures or completion.
* Women who are pregnant as well as women who are breast-feeding and do not consent to discontinue breast-feeding.
* Participation in another clinical trial within four weeks before start of therapy in this study.
* No consent for registration, storage and processing of the individual disease-characteristics.
* Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
* grapefruit or grapefruit products.
* Seville oranges (including marmalade containing Seville oranges).
* star fruit.
* Person of legal age who is incapable of comprehending the nature, significance and implications of the clinical trial and of determining his/her will in the light of these facts
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
Sponsor Role
collaborator
Zentrum für Klinische Studien Ulm
OTHER
Sponsor Role
collaborator
AbbVie
INDUSTRY
Sponsor Role
collaborator
Pfizer
INDUSTRY
Sponsor Role
collaborator
University of Ulm
OTHER
Sponsor Role
collaborator
University Hospital Schleswig-Holstein
OTHER
Sponsor Role
collaborator
Christian Buske
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Buske
Prof. Dr.
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Buske, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Ulm Department of Internal Medicine III
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, , Germany
Site Status
RECRUITING
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Site Status
RECRUITING
Klinikverbund Allgaeu gGmbH
Kempten, , Germany
Site Status
RECRUITING
Universitaetsklinikum Schleswig-Holstein AöR
Kiel, , Germany
Site Status
NOT_YET_RECRUITING
Gemeinschaftsklinikum Mittelrhein gGmbH
Koblenz, , Germany
Site Status
RECRUITING
Dr. Vehling-Kaiser MVZ GmbH
Landshut, , Germany
Site Status
RECRUITING
Kliniken Maria Hilf GmbH Moenchengladbach
Mönchengladbach, , Germany
Site Status
RECRUITING
Haematologie und Onkologie Muenchen-Pasing MVZ GmbH
München, , Germany
Site Status
RECRUITING
Universitaet Muenster
Münster, , Germany
Site Status
RECRUITING
University Hospital Ulm
Ulm, , Germany
Site Status
RECRUITING
Alexandra Hospital
Athens, , Greece
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Germany
Greece
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Buske C, Dimopoulos MA, Morel P. Reply to S. Sarosiek et al. J Clin Oncol. 2023 Aug 20;41(24):4060-4061. doi: 10.1200/JCO.23.00877. Epub 2023 Jun 22. No abstract available.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VIWA-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04285268
WITHDRAWN
PHASE2
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
NCT05025423
TERMINATED
PHASE2
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
NCT04061512
RECRUITING
PHASE2/PHASE3
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT06510309
NOT_YET_RECRUITING
PHASE2
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT03620903
ACTIVE_NOT_RECRUITING
PHASE2
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
NCT02658968
COMPLETED
PHASE1
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00041379
UNKNOWN
PHASE1/PHASE2
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787
COMPLETED
PHASE3
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
NCT04416451
ACTIVE_NOT_RECRUITING
PHASE2
PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
NCT02971982
UNKNOWN
PHASE1/PHASE2
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT04263480
ACTIVE_NOT_RECRUITING
PHASE2
Randomised Trial in Waldenstrom's Macroglobulinaemia
NCT01592981
COMPLETED
PHASE2
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
NCT04981912
ACTIVE_NOT_RECRUITING
PHASE1
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346
TERMINATED
PHASE2
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
NCT00142168
TERMINATED
PHASE2
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
NCT01779167
TERMINATED
PHASE2
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
NCT03806179
COMPLETED
PHASE1
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
NCT00397800
UNKNOWN
PHASE1/PHASE2
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
NCT02657447
WITHDRAWN
PHASE1
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
NCT01830465
COMPLETED
PHASE2
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632
COMPLETED
PHASE1/PHASE2
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
NCT02302469
COMPLETED
PHASE1/PHASE2
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
NCT04002401
COMPLETED
PHASE2
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
NCT01788020
COMPLETED
PHASE3
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
NCT06471738
RECRUITING
PHASE2